You may have access to the free features available through My Research. You can save searches, save documents, create alerts and more. Please log in through your library or institution to check if you have access.
If you log in through your library or institution you might have access to this article in multiple languages.
Styles include MLA, APA, Chicago and many more. This feature may be available for free if you log in through your library or institution.
You may have access to it for free by logging in through your library or institution.
You may have access to different export options including Google Drive and Microsoft OneDrive and citation management tools like RefWorks and EasyBib. Try logging in through your library or institution to get access to these tools.
You might have access to more details...
Try and log in through your library or institution to see if they have access.
For the management of bladder cancer, 2018 has been characterized by deepened knowledge on the molecular basis of invasive bladder cancer and its potential interaction with existing therapies, optimization of the use of immune checkpoint inhibitors, and emerging early signals on new therapeutic classes for advanced disease.
Key advances
The Cancer Genome Atlas performed a comprehensive characterization of muscle-invasive bladder cancer (MIBC) in a large cohort and proposed a framework of molecular subtypes with potential therapeutic approaches to inform future clinical trial design1.
The phase III RAZOR trial reported noninferior 2-year progression-free survival between robot-assisted radical cystectomy and open radical cystectomy2.
The phase II PURE-01 study reported that patients with MIBC and high programmed cell death 1 ligand 1 (PD-L1) expression had the highest response rates to neoadjuvant pembrolizumab5, warranting further evaluation in larger cohorts.
The phase III IMvigor211 trial did not report an overall survival benefit with atezolizumab over cytotoxic chemotherapy in locally advanced or metastatic urothelial carcinoma7.
Preliminary phase II findings demonstrated the efficacy of the fibroblast growth factor receptor 3 (FGFR3) inhibitor erdafitinib in metastatic urothelial cancer, leading to FDA Breakthrough Therapy Status for this drug10.
